bioAffinity Technologies, Inc. (NASDAQ: BIAF)

bioAffinity Technologies, Inc. develops noninvasive diagnostic laboratory tests to detect early stage lung cancer and other lung diseases using flow cytometry and automated analysis informed by machine learning.

The company's lead commercial product CyPath Lung analyzes cell populations in sputum to identify malignancy and provide physicians with a likelihood result.

In addition to CyPath Lung the company is advancing a flow cytometry and AI platform for companion diagnostics targeting asthma and chronic obstructive pulmonary disease.

Through its wholly owned subsidiary OncoSelect Therapeutics LLC the company conducts research on novel cancer therapeutic approaches that selectively target cancer cells.

Research and optimization activities are conducted in laboratories at its subsidiary PPLS and at leased space at the University of Texas at San Antonio.

The firm was incorporated in Delaware in March 2014 and maintains its principal executive office in San Antonio Texas.

bioAffinity emphasizes a scientific approach that combines proprietary biomarkers with advanced data analysis to improve patient outcomes.

Its strategy focuses on expanding the clinical utility of its platform while building a strong intellectual property foundation.

The company generates revenue primarily through the sale of its CyPath Lung diagnostic test performed by its certified clinical laboratory PPLS.

Physicians order the test for patients with indeterminate pulmonary nodules to aid in clinical decision making.

PPLS also provides traditional anatomic and pathology services which contributed to revenue prior to the company's strategic shift to focus on its diagnostic offering.

In addition the company receives reimbursement for CyPath Lung under the Medicare code 0406U and from private insurers.

Revenue is recognized when test results are delivered and reports are issued to ordering physicians.

The company has experienced growth in test volume driven by increased adoption among pulmonologists and oncologists.

Strategic initiatives to expand the sales force and to partner with distribution networks have contributed to higher test orders.

While the company has raised capital through equity offerings those transactions are financing activities not revenue streams.

bioAffinity Technologies operates in the lung cancer diagnostic market where it differentiates itself through a noninvasive sputum based test that combines flow cytometry with machine learning analysis.

The test offers high sensitivity and specificity comparable to more invasive procedures such as biopsy and bronchoscopy while avoiding radiation exposure and procedural risk.

Competitors in the space include blood based tests such as LungLB from LungLife AI and nodule assessment tools from Biodesix as well as gene expression tests like Percepta from Veracyte.

Additional competitors rely on imaging modalities such as low dose CT scans and PET scans which involve radiation exposure and higher costs.

bioAffinity's advantages stem from its proprietary synthetic porphyrin label its automated AI driven algorithm and its ability to be used both for initial detection and for surveillance of cancer survivors.

The company's strong intellectual property portfolio includes multiple issued patents covering the CyPath Lung assay and related therapeutic concepts.

Its CLIA certified CAP accredited laboratory provides a regulated environment that ensures quality and reliability of test results.

By focusing on a balanced diagnostic profile bioAffinity aims to capture market share from both rule out and rule in test segments.

The company serves physicians and healthcare providers who order the CyPath Lung test for patients at high risk of lung cancer.

Specific customers named in the filing include Brooke Army Medical Center the South Texas Audie L Murphy Memorial Veterans Medical Center Walter Reed Medical Center MD Anderson Cancer Center New York University Langone Medical Center and the University of Wisconsin School of Medicine and Public Health.

In addition the company works with Cardinal Health for logistical support of collection kits and sample transport.

The company also collaborates with various VA medical centers academic institutions and private clinics across the United States.

These relationships facilitate sample collection from diverse patient populations and support the generation of real world evidence.

Feedback from treating physicians helps inform product development and guides efforts to expand reimbursement coverage.

By maintaining a broad network of clinical partners bioAffinity seeks to increase test adoption and to build a sustainable commercial base.